BioNeutra Global Corporation
Other OTCTotal Valuation
BioNeutra Global Corporation carries a market capitalization of 260,113.00, placing it among publicly traded companies globally. Its enterprise value stands at 10.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 260,113.00 |
| Enterprise Value | 10.79M |
Share Statistics
BioNeutra Global Corporation currently has 46.45M shares outstanding.
| Shares Outstanding | 46.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.37, and the price-to-book ratio stands at -0.39.
| PE Ratio | N/A |
| PS Ratio | 0.37 |
| PB Ratio | -0.39 |
| P/TBV Ratio | -0.48 |
| P/FCF Ratio | -9.47 |
| P/OCF Ratio | -8.08 |
Enterprise Valuation
On an enterprise value basis, BioNeutra Global Corporation trades at an EV/EBITDA multiple of 94.82 and an EV/FCF ratio of 30.17.
| EV / Sales | 0.99 |
| EV / EBITDA | 94.82 |
| EV / EBIT | N/A |
| EV / FCF | 30.17 |
Financial Position
BioNeutra Global Corporation maintains a current ratio of 0.35, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -91.64, indicating conservative leverage, while an interest coverage ratio of 0.14 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.35 |
| Quick Ratio | 0.13 |
| Debt / Equity | -91.64 |
| Debt / EBITDA | 66.28 |
| Interest Coverage | 0.14 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -4.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 779.19 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.99 |
Stock Price Statistics
BioNeutra Global Corporation's stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioNeutra Global Corporation generated 10.86M in revenue and converted that into -610,204.00 in net income, yielding earnings per share of -0.01. EBITDA reached 113,797.00, while operating income came in at -343,476.00.
| Revenue | 10.86M |
| Gross Profit | 4.65M |
| Operating Income | -343,476.00 |
| Pretax Income | -610,204.00 |
| Net Income | -610,204.00 |
| EBITDA | 113,797.00 |
| EBIT | -343,476.00 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
BioNeutra Global Corporation holds 796,540.00 in cash and equivalents against 7.54M in total debt, resulting in a net debt position of 6.71M. Total book value stands at -10.50M, with working capital of -9.93M providing operational flexibility.
| Cash & Cash Equivalents | 796,540.00 |
| Total Debt | 7.54M |
| Net Debt | 6.71M |
| Equity (Book Value) | -10.50M |
| Book Value Per Share | -0.23 |
| Working Capital | -9.93M |
Cash Flow
BioNeutra Global Corporation produced -500,503.00 in operating cash flow over the past twelve months. After subtracting -72,468.00 in capital expenditures, free cash flow totaled -572,971.00 - equivalent to -0.01 per share.
| Operating Cash Flow | -500,503.00 |
| Capital Expenditures | -72,468.00 |
| Free Cash Flow | -572,971.00 |
| FCF Per Share | -0.01 |
Margins
BioNeutra Global Corporation operates with a gross margin of 42.84, reflecting its pricing power and cost economics. The operating margin of -3.16 and net profit margin of -5.62 provide insight into operational efficiency.
| Gross Margin | 42.84 |
| Operating Margin | -3.16 |
| Pretax Margin | -5.62 |
| Profit Margin | -5.62 |
| EBITDA Margin | 1.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 3.65 |
| FCF Yield | -10.56 |
Scores
BioNeutra Global Corporation posts an Altman Z-Score of -1.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.95 |